Foster Dykema Cabot & Co’s AtriCure ATRC Stock Holding History

Foster Dykema Cabot & Co’s Portfolio ATRC Stock Details ATRC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-137	Closed	-$7K	–	330
2023 Q2	$7K	Buy	+137	New	+$6.31K	﹤0.01%	273

Other funds holding ATRC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Foster Dykema Cabot & Co's ATRC Position: Q3 2023 in Review

Foster Dykema Cabot & Co sold out of AtriCure (ATRC) in Q3 2023, closing a stake of 137 shares — an estimated $7K sold.

Foster Dykema Cabot & Co first reported a position in ATRC in Q2 2023 and held it in 1 quarter. The position peaked at $7K in Q2 2023. 230 funds tracked by Wall St. Rank hold ATRC as of Q3 2023.

Foster Dykema Cabot & Co reported no remaining AtriCure position as of Q3 2023 after selling out during the quarter.
Foster Dykema Cabot & Co sold 137 AtriCure shares in Q3 2023, an estimated $7K.
Foster Dykema Cabot & Co first reported a position in AtriCure in Q2 2023 and held it in 1 quarter.
Foster Dykema Cabot & Co's AtriCure position peaked at $7K in Q2 2023.
230 funds tracked by Wall St. Rank held AtriCure as of Q3 2023.

Based on Foster Dykema Cabot & Co's 13F filing for Q3 2023, filed 14 Nov 2023.